KR102690131B1 - 바이러스 감염의 치료 및 예방을 위한 신규한 설폰이미도일푸린온 화합물 및 유도체 - Google Patents

바이러스 감염의 치료 및 예방을 위한 신규한 설폰이미도일푸린온 화합물 및 유도체 Download PDF

Info

Publication number
KR102690131B1
KR102690131B1 KR1020177035298A KR20177035298A KR102690131B1 KR 102690131 B1 KR102690131 B1 KR 102690131B1 KR 1020177035298 A KR1020177035298 A KR 1020177035298A KR 20177035298 A KR20177035298 A KR 20177035298A KR 102690131 B1 KR102690131 B1 KR 102690131B1
Authority
KR
South Korea
Prior art keywords
purin
methyl
compound
amino
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177035298A
Other languages
English (en)
Korean (ko)
Other versions
KR20180003612A (ko
Inventor
춘건 리앙
쿤 미아오
지엔핑 왕
홍잉 윤
시우팡 정
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55910966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102690131(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20180003612A publication Critical patent/KR20180003612A/ko
Application granted granted Critical
Publication of KR102690131B1 publication Critical patent/KR102690131B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177035298A 2015-05-08 2016-05-04 바이러스 감염의 치료 및 예방을 위한 신규한 설폰이미도일푸린온 화합물 및 유도체 Active KR102690131B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/078507 2015-05-08
CN2015078507 2015-05-08
CN2016078785 2016-04-08
CNPCT/CN2016/078785 2016-04-08
PCT/EP2016/059961 WO2016180695A1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (2)

Publication Number Publication Date
KR20180003612A KR20180003612A (ko) 2018-01-09
KR102690131B1 true KR102690131B1 (ko) 2024-07-31

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177035298A Active KR102690131B1 (ko) 2015-05-08 2016-05-04 바이러스 감염의 치료 및 예방을 위한 신규한 설폰이미도일푸린온 화합물 및 유도체

Country Status (32)

Country Link
US (3) US9708325B2 (https=)
EP (1) EP3294740B1 (https=)
JP (1) JP6738352B2 (https=)
KR (1) KR102690131B1 (https=)
CN (1) CN107580596B (https=)
AR (1) AR104528A1 (https=)
AU (3) AU2016260683B2 (https=)
BR (1) BR112017023959B1 (https=)
CA (1) CA2982704C (https=)
CL (1) CL2017002745A1 (https=)
CO (1) CO2017009994A2 (https=)
CR (1) CR20170496A (https=)
DK (1) DK3294740T3 (https=)
ES (1) ES2753777T3 (https=)
HR (1) HRP20191942T1 (https=)
HU (1) HUE045906T2 (https=)
IL (2) IL254947B (https=)
LT (1) LT3294740T (https=)
MX (2) MX376761B (https=)
MY (1) MY182353A (https=)
NZ (2) NZ775222A (https=)
PE (1) PE20171620A1 (https=)
PH (1) PH12017502009A1 (https=)
PL (1) PL3294740T3 (https=)
PT (1) PT3294740T (https=)
RS (1) RS59435B1 (https=)
RU (1) RU2745269C2 (https=)
SG (1) SG10202108841YA (https=)
SI (1) SI3294740T1 (https=)
TW (2) TWI706954B (https=)
UA (1) UA120450C2 (https=)
WO (1) WO2016180695A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3294740T3 (pl) * 2015-05-08 2020-03-31 F. Hoffmann-La Roche Ag Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych
AU2017320742B2 (en) 2016-08-29 2021-08-05 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
CN109715214B (zh) 2016-09-13 2022-03-04 豪夫迈·罗氏有限公司 Tlr7激动剂和hbv衣壳组装抑制剂的组合治疗
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ． ホフマン－ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
RU2020131012A (ru) * 2018-02-28 2022-03-28 Ф. Хоффманн-Ля Рош Аг 7-замещенные соединения сульфонимидоилпуринонов и их производные для лечения и профилактики рака печени
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
JP7695885B2 (ja) * 2019-02-12 2025-06-19 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
JP7581336B2 (ja) 2019-09-20 2024-11-12 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 硫黄及びスルホキシミン含有置換基を有する殺有害生物的に活性な複素環式誘導体
US20230131192A1 (en) * 2020-01-27 2023-04-27 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
JP2023512204A (ja) * 2020-01-27 2023-03-24 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
CN119604517A (zh) 2022-07-14 2025-03-11 豪夫迈·罗氏有限公司 用于治疗癌症的磷酰基嘌呤酮化合物
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006117670A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
US20100143301A1 (en) 2008-12-09 2010-06-10 Gilead Sciences, Inc. Modulators of toll-like receptors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TW201636330A (zh) * 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
RS57851B1 (sr) * 2011-11-09 2018-12-31 Janssen Sciences Ireland Uc Purinski derivati za tretman viralnih infekcija
AU2014242954B2 (en) 2013-03-29 2018-03-15 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
HUE054672T2 (hu) 2014-08-15 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co Ltd TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek
PL3294740T3 (pl) * 2015-05-08 2020-03-31 F. Hoffmann-La Roche Ag Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych
AU2017320742B2 (en) * 2016-08-29 2021-08-05 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006117670A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
US20100143301A1 (en) 2008-12-09 2010-06-10 Gilead Sciences, Inc. Modulators of toll-like receptors

Also Published As

Publication number Publication date
PT3294740T (pt) 2019-10-29
CN107580596B (zh) 2020-07-14
AR104528A1 (es) 2017-07-26
NZ775222A (en) 2024-09-27
JP6738352B2 (ja) 2020-08-12
HUE045906T2 (hu) 2020-01-28
LT3294740T (lt) 2019-11-25
AU2016260683B2 (en) 2020-10-29
TW201716410A (zh) 2017-05-16
NZ735648A (en) 2023-06-30
SG10202108841YA (en) 2021-09-29
KR20180003612A (ko) 2018-01-09
EP3294740B1 (en) 2019-09-04
US11242345B2 (en) 2022-02-08
US20200109144A1 (en) 2020-04-09
US20170275286A1 (en) 2017-09-28
MX2017014033A (es) 2018-03-01
CN107580596A (zh) 2018-01-12
HK1247925A1 (zh) 2018-10-05
CR20170496A (es) 2017-12-05
CA2982704A1 (en) 2016-11-17
RU2745269C2 (ru) 2021-03-22
MX2020010949A (es) 2022-06-16
ES2753777T3 (es) 2020-04-14
UA120450C2 (uk) 2019-12-10
IL280769A (en) 2021-04-29
DK3294740T3 (da) 2019-11-04
MY182353A (en) 2021-01-20
MX393198B (es) 2025-03-19
TW202108584A (zh) 2021-03-01
AU2016260683A1 (en) 2017-10-12
RU2017142577A (ru) 2019-06-10
HRP20191942T1 (hr) 2020-01-10
MX376761B (es) 2025-03-07
IL254947A0 (en) 2017-12-31
RS59435B1 (sr) 2019-11-29
JP2018515509A (ja) 2018-06-14
IL280769B1 (en) 2023-03-01
US20160326177A1 (en) 2016-11-10
BR112017023959A2 (pt) 2018-07-17
TWI768467B (zh) 2022-06-21
PH12017502009A1 (en) 2018-03-26
EP3294740A1 (en) 2018-03-21
PL3294740T3 (pl) 2020-03-31
US9708325B2 (en) 2017-07-18
CA2982704C (en) 2023-10-24
CL2017002745A1 (es) 2018-05-18
SI3294740T1 (sl) 2019-12-31
TWI706954B (zh) 2020-10-11
RU2017142577A3 (https=) 2019-10-31
US10399983B2 (en) 2019-09-03
BR112017023959B1 (pt) 2023-05-02
AU2020256348B2 (en) 2022-06-16
IL280769B2 (en) 2023-07-01
AU2022204666A1 (en) 2022-07-21
IL254947B (en) 2021-02-28
WO2016180695A1 (en) 2016-11-17
CO2017009994A2 (es) 2018-02-20
PE20171620A1 (es) 2017-11-02
AU2020256348A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
KR102690131B1 (ko) 바이러스 감염의 치료 및 예방을 위한 신규한 설폰이미도일푸린온 화합물 및 유도체
KR102030305B1 (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
CA3232128A1 (en) Pyridine derivative and use thereof
RU2540332C2 (ru) Бициклические азотсодержащие гетероциклические соединения, полезные при лечении гепатита с
JP2022549274A (ja) ホスホジエステラーゼ阻害剤および使用
JP6605493B2 (ja) 新規大環状化合物
JP6888000B2 (ja) 新規な修飾された大環状化合物
JP2022551254A (ja) ヒト免疫不全ウイルスの複製阻害剤
CA3057891A1 (en) Novel ptefb inhibiting macrocyclic compounds
JP2017511325A (ja) スルホンジイミン基を含むジ置換５−フルオロピリミジン誘導体
KR20180025928A (ko) 인간 면역결핍 바이러스 복제의 억제제로서 피리딘-3-일 아세트산 유도체
HK1247925B (zh) 用於治疗和预防病毒感染的新的磺亚氨酰基嘌呤酮化合物和衍生物
TWI835344B (zh) 新穎蛋白殼組裝抑制劑
TW202502763A (zh) 治療發炎性疾病之方法
HK40067638A (en) Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000